Professors Huafeng Wang and Mikkael Sekeres Discuss ASH Guidelines Update for Elderly AML Patients and Its Implications for Treatment Pathways in China

Professors Huafeng Wang and Mikkael Sekeres Discuss ASH Guidelines Update for Elderly AML Patients and Its Implications for Treatment Pathways in China

2025.12.13
On December 7th, local time, the highly anticipated session on the "Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults" was successfully held at the American Society of Hematology (ASH) Annual Meeting. This session was chaired by Professor Mikkael Sekeres, the lead expert of the ASH guidelines and Director of the Department of Hematology at Sylvester Comprehensive Cancer Center. To gain deeper insights into the key points of the guideline update and the emerging trends it reflects, Oncology Frontier- Hematology Frontier invited Professor Huafeng Wang from Zhejiang University School of Medicine’s First Affiliated Hospital to engage in a deep dialogue with Professor Sekeres.
ESMO Asia 2025 | Professor George Lau: HR 0.60！STRIDE regimen Chinese population data impressively unveiled, dual immunotherapy efficacy significantly

ESMO Asia 2025 | Professor George Lau: HR 0.60！STRIDE regimen Chinese population data impressively unveiled, dual immunotherapy efficacy significantly

2025.12.11
From December 5 to 7, 2025, the highly anticipated European Society for Medical Oncology Asia Congress (ESMO Asia 2025) was grandly held in Singapore. During the Mini Oral Session: Gastrointestinal Tumours, Professor George Lau, Chairman of the Hong Kong Humanity Medical Group and Director of the Humanity Medical Clinical Research CenterSenior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Center, Principal Investigator of the Humanity and Health Clinical Trial Center, as well as a physician Honorary Professor and Senior Consultant at Zhongshan Hospital Affiliated to Fudan University, was invited to deliver an oral presentation. For the first time, he shared the research data on the treatment of Asian patients with unresectable hepatocellular carcinoma (HCC) using Tremelimumab in combination with Durvalumab. This study is based on a sample that more closely reflects the epidemiological characteristics and disease spectrum of Asian patients, providing high-quality evidence-based medical evidence with targeted relevance. It lays a solid foundation for optimizing and advancing the individualization and precision of liver cancer treatment strategies in this region.